ArticleFrontiers in neurology2024

Improvements in no evidence of disease activity with ublituximab vs. teriflunomide in the ULTIMATE phase 3 studies in relapsing multiple sclerosis.

Enrique Alvarez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.